Entry into and withdrawal from NKT-cell therapy and blockchain businesses through the acquisition of RIRM
A theme involving the acquisition of RIRM as a subsidiary and planned entry into NKT-cell cancer immunotherapy technology and a blockchain-based platform business, followed by the transfer of all shares and withdrawal from both businesses.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.